GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies September 13, 2021
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies September 9, 2021
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer August 23, 2021
GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota July 7, 2021
GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit June 24, 2021
